| Original language | English |
|---|---|
| Pages (from-to) | 837-841 |
| Number of pages | 5 |
| Journal | Cancer Drug Resistance |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2021 |
Bibliographical note
Funding Information:van Waardenburg RCAM in part funded by American Cancer Society UAB ACS-IRG Junior Faculty Development Grant (ACS-IRG-60-001-53), Department of Defense OCRP pilot award W81XWH-15-1-0198, and the National Institutes of Health Cancer Center Core Support Grant (P30CA013148) and National Institutes of Health - National Institute of Disorders and Stroke (1R21NS116312-01A1).
Funding
van Waardenburg RCAM in part funded by American Cancer Society UAB ACS-IRG Junior Faculty Development Grant (ACS-IRG-60-001-53), Department of Defense OCRP pilot award W81XWH-15-1-0198, and the National Institutes of Health Cancer Center Core Support Grant (P30CA013148) and National Institutes of Health - National Institute of Disorders and Stroke (1R21NS116312-01A1).
| Funders | Funder number |
|---|---|
| Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council | 1R21NS116312-01A1 |
| National Institutes of Health (NIH) | P30CA013148 |
| National Institutes of Health (NIH) | |
| U.S. Department of Defense | W81XWH-15-1-0198 |
| U.S. Department of Defense | |
| American Cancer Society-Michigan Cancer Research Fund | ACS-IRG-60-001-53 |
| American Cancer Society-Michigan Cancer Research Fund |
ASJC Scopus subject areas
- Cancer Research
- Pharmacology (medical)
